Arrowhead Pharmaceuticals (ARWR) fundamentals: P/E, valuation, undervalued?
Arrowhead Pharmaceuticals · Health Care · ref. ETF XLV · price $88.59
In short — Arrowhead Pharmaceuticals trades at —× earnings (P/E), -18.2× forward, with a net margin of -47.8 % and revenue growth of +171 %. Read: Not (yet) profitable (valued on growth, not earnings).
Is Arrowhead Pharmaceuticals stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$88.59+296.6% over range
Aug 28, 25low $22.03 · high $89.59Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
80% recommend buying · 10 analysts
Valuation : Not (yet) profitable — valued on growth, not earnings
Valuation
—
P/E (price/earnings)
-18.2
Forward P/E
—
PEG
26.9
Price/book (P/B)
$12.5B
Market cap
-2.27
EPS
Profitability & growth
-47.8 %
Net margin
+171 %
Revenue growth
—
Earnings growth
$1.4B
Total debt
Arrowhead Pharmaceuticals income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $243M | $-176M | -72.4 % |
| 2023 | $241M | $-205M | -85.3 % |
| 2024 | $4M | $-599M | -16882.4 % |
| 2025 | $829M | $-2M | -0.2 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Arrowhead Pharmaceuticals's P/E and is the stock undervalued? What's a good P/E?
Arrowhead Pharmaceuticals's P/E is — (forward -18.2). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Not (yet) profitable".
Is Arrowhead Pharmaceuticals profitable?
Arrowhead Pharmaceuticals has a net margin of -47.8 % (EPS -2.27). The company is not (yet) profitable.
Is ARWR stock expensive?
Our read: "Not (yet) profitable" — valued on growth, not earnings. Cross-check with growth and sector.
💬 A question about Arrowhead Pharmaceuticals? The JPI assistant answers using our backtest data.
Keep exploring Arrowhead Pharmaceuticals